Cloud Pharmaceuticals, a cloud-based drug design and development company, is interested in potential collaborations around myotonic dystrophy targets.
Cloud Pharmaceuticals designs targeted therapeutics using cloud-based high performance computing platforms and delivers novel molecular designs of ligands to druggable targets.
The company's Quantum Molecular Design process has three components:
- Produce virtual chemical space and search for novel drug scaffolds
- Accurate prediction of ligands binding to the protein active site
- Expert system to choose the molecules with the highest probability of becoming drugs
An article describing their technology has just been published (geared toward non-experts).
Contact Chief Science Officer Dr. Shahar Keinan at email@example.com.
Are you currently doing DM work or seeking DM-related collaborations? Please contact MDF’s Chief Science Officer, Dr. Sharon Hesterlee at firstname.lastname@example.org.